



TELOGENOMICS

WORLD-LEADING
Telomere-based
diagnostic/prognostic
platform

TSXV: TELO | OTCQB: TDSGF

**Corporate
Update**


Forward Looking Statement & Disclosures

This document and any attachments are intended for information purposes only and should not be construed as an offer or solicitation for the sale of securities. Statements in this presentation include forward-looking statements within the meaning of certain securities laws. These forward-looking statements include, among others, statements with respect to our objectives, goals and strategies to achieve those objectives and goals, as well as statements with respect to our beliefs, plans, objectives, expectations, anticipations, estimates and intentions. The words “expected to” “illustrate” “has the potential to” “will be”, “evaluating” “plans” “can be” “planning” “to predict” “potential” “may” “should” and words and expressions of similar import, are intended to identify forward-looking statements. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not put undue reliance on these statements, or the scientific data presented as a number of important factors, many of which are beyond our control, could cause our actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. We do not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf; such statements speak only as of the date made. The forward-looking statements included herein are expressly qualified in their entirety by this cautionary language.

Clinical Challenges Telo Genomics is solving in large markets


Over \$4 billion diagnostic market for MRD in 2030 (1)

First company to add risk profiling to the enumeration of MRD for multiple myeloma and other cancers through a liquid biopsy test performed in Telo's CLIA/CAP certified lab




Over \$8 billion diagnostic market for Alzheimer's disease (2)

Telo Genomics will provide tools for detecting Alzheimer's disease **non-invasively** at its earliest (preclinical) stages, before significant symptoms appear



Over \$9 billion diagnostic market for Prostate cancer (3)

Telo Genomics' prostate cancer test is distinguishing between clinically significant (aggressive) and indolent (slow-growing, non-harmful) disease



Telo Genomics's solutions are non-invasive, repeatable, affordable and drive very important actionable clinical information that dramatically affects the patient's quality of life and saves overall costs for healthcare.

The Science behind Telo Genomics and Genomic Instability

What is genomic instability?

Genomic instability is a hallmark of cancer. It is dynamic and alters the genome, often creating cell-to-cell heterogeneity. Genomic instability can involve small or large changes and may include gains and losses of chromosomes or of parts of chromosomes. Small changes include point mutations; large changes include structural rearrangements.



The role of Telomeres in identifying genomic instability

Telomeres are the ends of chromosomes and act as their protective caps. Without telomeres, chromosomes become unstable and often fuse with each other. Such end-to-end fused chromosomes initiate breakage-bridge fusion cycles during cell division. These in turn create Robertsonian chromosomes, terminal deletions and unbalanced translocations, which again give rise to more genomic instability



The impact of telomeric changes

Telomeric changes are not only changes in telomere length but also changes in the three-dimensional (3D) spatial organization of telomeres within the nuclei of cells. **Telo Genomics' TeloView® software measures, on a single cell level, the 3D spatial organization of telomeres while also determining their numbers, their individual length and their cell cycle-dependent organization.** Current technologies only offer measurement of average Telomere lengths, limiting the understanding of telomere changes at the single cell levels

Investment Highlights

Addressing important clinical needs in very large markets



- First company to add risk profiling to the enumeration of MRD for multiple myeloma and other cancers through a liquid biopsy test
- Providing tools for detecting Alzheimer's disease at its earliest (preclinical) stages, before significant symptoms appear
- Telo Genomics' prostate cancer test is distinguishing between clinically significant (aggressive) and indolent (slow-growing, non-harmful) disease

Leading provider of Telomere based prognostic molecular solutions



- Technology evaluated across multiple disease areas including prostate cancer, lung cancer, breast cancer, leukemia and neurodegenerative disease
- First company developing a complete product offering for multiple myeloma [smoldering multiple myeloma, newly diagnosed multiple myeloma, minimal residual disease]
- Products offered through our CLIA/CAP certified lab

New Leadership Team



- New leadership team brings extensive experience to accelerate CAP/CLIA certified clinical products while maintaining a low burn
- Experienced in building successful partnership with leading clinical institutions & industry partners for licensing deals
- Expand IP portfolio
- **Focus on the US market with potential up listing to NASDAQ**

Technology has been evaluated in collaboration with leading US clinical institutions



Providing novel clinical application across multiple disease areas supported by leading clinical institutions, validated in over 160 peer reviewed publications

Leadership Team & Board members



Guido Baechler

Executive Chairman



Dr. Sabine Mai

**Interim CEO, Director
& Co-founder**



Chris Ross, CPA, CGA

CFO



Mark Stene, PhD, MBA

**Head of Laboratory
Operations**



Dr. Ron McGlennen

Director



John Farlinger

Director



Dr. Hans Knecht


**Medical Laboratory
Director**

TeloView® was extensively validated with over 160 peer reviewed publications to measures disease initiation, evolution and progression by analyzing telomere dynamics on a tissue-agnostic platform


Telomere parameters quantified
by TELOVIEW®



Healthy cell




Diseased cell



Using FISH labeling and high-resolution microscopy, the 3D spatial structure of each telomere is visualized and digitally analyzed. The diseased cell show aggregates, extremely small telomeres, nuclear spaces without telomeres and different telomere numbers

AI supported Workflow for Teloview Platform

TeloView Technology is Agnostic to Sample Type (from blood, urine, etc.) and can be used across many disease areas



* FISH is an imaging technique that is widely available in standard diagnostic labs
Alzheimer's test only needs FISH and not Immuno-FISH

Product Pipeline

Program	Indication	Feasibility	Development	Clinical Validation	Commercial (LDT)	Notes
Multiple Myeloma (MM)	Smoldering Multiple Myeloma (SMM)					Pre-commercial with SMART protocol
	Minimal Residual Disease (MRD)				Q4/2025	Validation with Cleveland Clinic
	First-line therapy management					Validation with Mayo & other clinical centers
Alzheimer's disease (AD)	Mild Alzheimer's disease identification				Q1/2026	Development & validation with Sunnybrook University
Prostate cancer (PC)	Intermediate risk prediction (blood)					Training finalized, pending validation study

TELO GENOMICS MM PROGNOSTIC SOLUTIONS

INITIATION




Clonal Plasma cells



PROGRESSION

Clonal, malignant plasma cells



Normal mature plasma cells

Asymptomatic lower risk precursor of MM

Asymptomatic higher risk precursor of MM

Symptomatic full stage disease

Post-germinal central B cell

Monoclonal Gammopathy of Undetermined Significance
MGUS

Smoldering Multiple Myeloma

Multiple Myeloma

Telo Genomics Myeloma Product Pipeline

TeloView SMM

TeloView NDMM

TeloView MRD
Enumeration and Profiling


Predicts patient's risk of progression to full stage disease

Identifies newly diagnosed patients risk of relapse on standard therapy

Unique assessment of treatment response based on risk profiling of individual MRD cells


Minimum Residual Disease (MRD) for Multiple Myeloma

Monitoring MRD over time can detect residual cells that may lead to disease relapse. Identification of high-risk vs low risk patients is needed



- TeloMRD is a complete **liquid biopsy-based test**. New guidelines are moving away from bone marrow to liquid biopsy (blood sample)
- **Telo's MRD test achieved a sensitivity of 1 in 10,000,000 cells** compared to competitive technologies of 1 in 100,000 and 1 in 1,000,000. The detection limit is for identified cancer cells directly and not inferred through amplification of bio markers
- The genomic instability profiling provided by the Telo MRD test **enables differentiation of aggressive clones of MRD cells with a tendency to cause earlier relapse versus benign clones of MRD cells**


Clinical development and validation initiated in partnership with Cleveland clinic.



Using Teloview® for early detection of mild Alzheimer's


- Of the 57 million people living with dementia worldwide, [60-70% are thought to have Alzheimer's disease](#).
- The most common form of dementia, Alzheimer's, is a brain disorder characterized by the slow erosion of a person's memory and thinking skills. In the US alone, it is the [sixth leading cause of death](#), and while lifestyle changes and medication can help ease symptoms, **there is currently no cure**.
- With the number of people with dementia expected to increase to [150 million by 2050](#), the pressure is on to find a solution to this debilitating and devastating disease.
- The main challenge for detecting Alzheimer's disease is the difficulty of diagnosing the disease at its earliest (preclinical) stages, before significant symptoms appear

Telo Genomics has shown in multiple clinical studies the ability to identify Alzheimer's disease using a simple and inexpensive buccal swab combined with the Teloview® technology



All data from <https://www.weforum.org/stories/2025/06/recent-breakthroughs-fight-against-alzheimers-disease/>

Using TeloView® for early detection of mild Alzheimer's



TeloView's mild AD's and MCI test can be used as initial screening test to complement the clinical evaluation or potential replace the clinical evaluation enabling more subjects to benefit from the current anti-amyloid therapies

Clinical data using Telomere lengths

Key non-Telo publications

Reference	Disease	Sample	Measurement Method, Tissue	Observed Difference	Statistical Significance
Forero et al., 2016	Alzheimer's Disease (AD)	In combination of 13 studies, analyzed 860 AD patients and 2,022 control	Meta-analysis, various methods, various tissues	Standardized mean difference of -0.984 in telomere length between AD patients and controls	$p < 0.001$
Scarabino et al., 2019	Huntington's disease (HD)	62 HD patients, 38 pre-manifest HD patients, 76 age-matched controls	qPCR, blood	Telomeres lengths decreased from healthy > pre-HD > HD	$p < 0.00001$
De Felice et al., 2014	Amyotrophic Lateral Sclerosis (ALS)	50 ALS patients and 50 controls	qPCR, blood	15% shorter telomeres in ALS patients compared to controls	$p < 0.05$
Al Khleifat et al., 2019	Amyotrophic Lateral Sclerosis (ALS)	1241 ALS and 335 controls	Telomere lengths were estimated from whole-genome sequencing, leukocytes	9% longer telomeres in ALS patients compared to controls	$p = 0.03$
Krysko et al., 2019	Multiple Sclerosis (MS)	516 MS patients	qPCR, blood	Shorter telomeres associated with greater disability progression in MS patients	$p < 0.001$

Non-Telo publication so far have mostly focused on **Telomere lengths**


Disease areas covered:

- Alzheimer's disease (AD)
- Amyotrophic lateral sclerosis (ALS)
- Mixed dementia
- Lewy body dementia (LBD)
- Mild cognitive. Impairment (MCI)
- Parkinson's disease (PD)

AD identification using Teloview® technology

Mathur et al 2014:

Three-Dimensional Quantitative Imaging of Telomeres in Buccal Cells Identifies Mild, Moderate, and Severe Alzheimer's Disease Patients



Garcia et al 2017:


Three-Dimensional Quantitative Imaging of Telomeres in Buccal Cells Identifies Mild, Moderate, and Severe Alzheimer's Disease Patients

Sunnybrook study 2025 :

A Prospective Cross-Sectional, Quantitative 3D Telomeric Imaging Study of Buccal Cells in Mild Alzheimer's Disease Patients

Interim analysis using TeloView parameters shows a **95% sensitivity at 95% specificity** for detecting mild Alzheimer's patients compared for detecting mild Alzheimer's patients compared to cognitive tests, amyloid-PET (18 subjects had amyloid-PET test, 16/18 positive) and tau-PET (2 subjects had tau-PET test, 2/2 positive).

Clinical development and validation initiated in partnership with Sunnybrook Hospital (Dr. Black)



Using TeloView® for Prostate cancer


Clinical challenge:

The biggest challenge for diagnosing prostate cancer is **distinguishing between clinically significant (aggressive) and indolent (slow-growing, non-harmful) disease**.

While tools like PSA testing and multiparametric MRI have greatly improved early detection, they also often lead to overdiagnosis and overtreatment—identifying cancers that would never have caused symptoms or harmed the patient if left undiscovered.

- *This results in unnecessary interventions that may cause complications such as urinary incontinence and erectile dysfunction, reducing quality of life.*
- ***What's needed: Liquid biopsy test stratifying patients with Gleason 7 scores without requiring a biopsy***

TeloView has shown utility in risk stratifying the disease course of intermediate Gleason Score patients, without requiring a biopsy, addressing the important unmet need to avoid unnecessary surgery for over 30% of newly diagnosed PC patients



Summary Financial & IP

As of August 2, 2025

SHARES
OUTSTANDING

100.4M

SHARE PRICE
8/02/25

\$0.08CAD

OPTIONS

4.2M

MARKET CAP

\$8MCAD

WARRANTS

28.7M

CASH POSITION
03/31/25

\$1.2MCAD

FULLY DILUTED
SHARES

133.4M

BURN RATE

\$150KCAD/
MONTH

Management % of outstanding shares: 4.01%

19

19 Patents in
Canada, USA &
Europe **with**
longevity up to
2043


\$25M +

Over \$25M non-
dilutive R&D funding

>3000


Over 3000 patients
evaluated

Key Upcoming Milestones to drive shareholder value



Expanding to US based investors with the goal to up listing Telo Genomics to Nasdaq in the near future

Investment Highlights





TELOGENOMICS

Corporate
Update

WORLD-LEADING
Telomere-based
diagnostic/prognostic
platform

101 College St, Suite 200, Toronto, Canada

Info@teloddx.com

647 477 9365